Targeted inhibition of gut microbiota proteins involved in TMAO production to reduce platelet aggregation and arterial thrombosis: a blueprint for drugging the microbiota in the treatment of cardiometabolic disease?
J Thromb Haemost
.
2019 Jan;17(1):3-5.
doi: 10.1111/jth.14331.
Epub 2018 Dec 10.
Authors
T E van Mens
1
,
H R Büller
1
,
M Nieuwdorp
1
2
Affiliations
1
Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
2
Departments of Internal Medicine, Amsterdam Diabetes Center, Amsterdam University Medical Centers, AMC and VUMc, Amsterdam, the Netherlands.
PMID:
30548165
DOI:
10.1111/jth.14331
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Gastrointestinal Microbiome*
Humans
Methylamines
Microbiota*
Platelet Aggregation
Thrombosis*
Substances
Methylamines
trimethyloxamine
Grants and funding
016.146.327/ZONMW-VIDI/International
17CVD01/Fondation Leducq/International
Dutch Heart Foundation/International